Reflections on 10 years of the FDA’s breakthrough therapy designation

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2022年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ellen Sigal, the founder of Friends of Cancer Research, discusses the origins and future of the FDA’s breakthrough therapy designation as well as the changing patient advocacy landscape.
引用
收藏
页码：252 / 253
页数：1
相关论文
共 50 条
  • [1] Reflections on 10 years of the FDA's breakthrough therapy designation
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 252 - 253
  • [2] Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update
    Paquin, Ryan S.
    Boudewyns, Vanessa
    O'Donoghue, Amie C.
    Aikin, Kathryn J.
    ONCOLOGIST, 2022, 27 (01): : E85 - E88
  • [3] Breakthrough-Therapy Designation - An FDA Perspective
    Corrigan-Curay, Jacqueline
    Mckee, Amy E.
    Stein, Peter
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15): : 1457 - 1458
  • [4] Rapastinel receives FDA breakthrough therapy designation
    不详
    NURSE PRACTITIONER, 2016, 41 (04): : 56 - 56
  • [5] Expediting Drug Development - The FDA's New "Breakthrough Therapy" Designation
    Sherman, Rachel E.
    Li, Jun
    Shapley, Stephanie
    Robb, Melissa
    Woodcock, Janet
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20): : 1877 - 1880
  • [6] The FDA Breakthrough-Drug Designation - Four Years of Experience
    Darrow, Jonathan J.
    Avorn, Jerry
    Kesselheim, Aaron S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15): : 1444 - 1453
  • [7] FDA Grants Breakthrough Therapy Designation to Magrolimab for MDS Treatment
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (10): : 430 - 430
  • [8] Breakthrough therapy: FDA's new designation for accelerating approval of promising pipeline therapies
    Calabrese, David
    FORMULARY, 2013, 48 (08) : 275 - 276
  • [9] IS FDA'S BREAKTHROUGH THERAPY DESIGNATION A GAME-CHANGING TREND FOR PATIENTS AND PAYERS?
    Aggarwal, S.
    Topaloglu, H.
    VALUE IN HEALTH, 2014, 17 (03) : A10 - A10
  • [10] FDA Grants Breakthrough Therapy Designation to Tiragolumab Atezolizumab Therapy for Metastatic NSCLC
    Slater, Hannah
    ONCOLOGY-NEW YORK, 2021, 35 (02): : 76 - 76
12345